Literature DB >> 24034038

Inhaled nitric oxide versus sodium nitroprusside for preoperative evaluation of pulmonary hypertension in heart transplant candidates.

D Pasero1, N K Rana, R Bonato, M Ribezzo, F Ivaldi, D Ricci, W Grosso Marra, L Checco, M Lupo, M Boffini, M Rinaldi.   

Abstract

OBJECTIVE: The development of pulmonary hypertension before heart transplantation increases the risk for postoperative right ventricular failure. Reversibility of pulmonary vascular resistance (PVR), which indicates the feasibility of heart transplantation, can be tested with the use of intravenous vasodilators, such as sodium nitroprusside (NaNTP) or prostacyclin. However, the drawback of these drugs is the development of systemic hypotension. The aim of this study was to evaluate the safely and feasibility of inhaled nitric oxide (iNO) compared with sodium nitroprusside to test PVR reversibility, while avoiding systemic hypotension.
MATERIALS AND METHODS: We included all patients who were affected by end stage heart failure undergoing evaluation for heart transplantation if they showed elevated PVR > 2.5 Wood units and mean pulmonary arterial pressure (mPAP) >25 mm Hg. The hemodynamic parameters measured by right heart catheterization were: systolic blood pressure (SBP), mPAP, pulmonary capillary wedge pressure, and cardiac index (CI). The following variables were derived: transpulmonary gradient (TPG) and PVR. All patients were tested by both iNO (20-40 ppm) and intravenous NaNTP, at increasing dosages which were titrated based on systemic pressure. We randomly assigned the order of administration of iNO and NaNTP.
RESULTS: The 9 male candidates has an average age of 56 ± 4 years. Seven of the 9 (71%) had postischemic cardiomyopathy, and 2 had idiopathic cardiomyopathy. We observed a reduction of mPAP (32% and 14%), PVR (41% and 32%), TPG (20% and 26%), and SBP (17% and 5%) and an increase of CI with administration of NaNTP and iNO, respectively.
CONCLUSIONS: We observed a reduction in PVR and mPAP with administration of either iNO and NaNTP. A better effect of NaNTP was attributed to reducted post-load of the left ventricle. However, the main advantage of iNO was the absence of systemic hypotension and its selectivity for pulmonary vascular system, as underscored by TPG reduction.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24034038     DOI: 10.1016/j.transproceed.2013.07.044

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  5 in total

Review 1.  Nitric oxide: what's new to NO?

Authors:  Kedar Ghimire; Helene M Altmann; Adam C Straub; Jeffrey S Isenberg
Journal:  Am J Physiol Cell Physiol       Date:  2016-12-14       Impact factor: 4.249

Review 2.  Management of pulmonary hypertension from left heart disease in candidates for orthotopic heart transplantation.

Authors:  Anna Koulova; Alan L Gass; Saikrishna Patibandla; Chhaya Aggarwal Gupta; Wilbert S Aronow; Gregg M Lanier
Journal:  J Thorac Dis       Date:  2017-08       Impact factor: 2.895

Review 3.  Pulmonary Hypertension in the Era of Mechanical Circulatory Support.

Authors:  Yamini Krishnamurthy; Lauren B Cooper; Kishan S Parikh; G Michael Felker; Carmelo A Milano; Joseph G Rogers; Adrian F Hernandez; Chetan B Patel
Journal:  ASAIO J       Date:  2016 Sep-Oct       Impact factor: 2.872

4.  Prolargin and matrix metalloproteinase-2 in heart failure after heart transplantation and their association with haemodynamics.

Authors:  Abdulla Ahmed; Salaheldin Ahmed; Mattias Arvidsson; Habib Bouzina; Jakob Lundgren; Göran Rådegran
Journal:  ESC Heart Fail       Date:  2019-12-19

5.  Haemodynamic effects and potential clinical implications of inhaled nitric oxide during right heart catheterization in heart transplant candidates.

Authors:  Christopher Strong; Luís Raposo; Mariana Castro; Sérgio Madeira; António Tralhão; António Ventosa; Maria José Rebocho; Manuel Almeida; Carlos Aguiar; José Pedro Neves; Miguel Mendes
Journal:  ESC Heart Fail       Date:  2020-02-11
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.